@EASLnews @EASLedu @gregpavillon @EASL_Sec_Gen @mcolombo46 Congrats to EASL team/leadership for an outstanding #ilc2017 in Amsterdam

@EASLedu synchronous cell phone cameras rise among the audience to capture closing session highlights #ilc2017

Avoid using "immunotolerant" and "inactive carrier" in #HBV per @EASLnews guidelines: a very welcome and long overdue statement #ilc2017

@EASLedu Prof. Wedemeyer: neuralgic amyotrophy now well documented extrahepatic manifestation of #HEV ?replicates outside liver #ilc2017

@EASLedu 1/900 blood donations in Hamburg (northern Germany) #HEV Ab positive. Sobering news from northern Germany #ilc2017

Prof Wedemeyer: #HAV and #HEV may be risk factors for autoimmune hepatitis based on German data #ilc2017

@EASLedu Prof. Wedemeyer tackles last but not least presentation of #ILC2017: the Hepatitis debrief

@EASLedu you can dl myfibroscan app by @Echosens and calculate prob. active #NAFLD (PAN) score based on #fibroscan & CAP scores #ilc2017

@EASLedu Prof Ratziu: practically useful but still "mysterious" algorithm to predict #NASH based on CAP and #fibroscan score. #ILC2017

@EASLedu Prof. Ratziu: promising trial of NGM282 rapidly reduces fat and ALT in #NASH but raises LDL #ILC2017

@EASLedu Prof Ratziu: promising data for #BMS-986036 in #NASH reducing fat fraction and pro-c3 (antifibrogenic effect?) #ILC2017

@EASLedu CheckMate-040 study of #nivolumab in #HCC #sorafenib failures. Note overall survival not yet reached for #HCV and #HBV #ilc2017

@EASLedu Prof. Dufour highlights data showing CAP >220 dB/m can help predict decompensation in high #fibroscan score pts #ilc2017

@EASLedu highlight 3 from #ilc2017 are 8 wk #glecaprevir #pibrentasvir near 100% cure with #HCV GT1-6 non cirrhotics #ilc2017

@EASLedu Highlight 2 from #ilc2017 are #nivolumab data in #HCC #sorafenib failures showing high disease control rate and survival

@EASLedu Highlight 1 from #ilc2017 is #bezafibrate RCT data in #PBC non responders. If confirmed, great news for @PBCers worldwide

@EASLedu Dr. Maistat: most access in Belarus is through "buyers' clubs" in India and Egypt since cost otherwise prohibitive #ilc2017

@EASLedu Dr. Maistat: the prevalence of #HCV in Ukraine is 8%. Shocking to me #ilc2017

@EASLnews @AASLDtweets As #ilc2017 winds down, we look forward to seeing all in Washington DC for the liver meeting, oct 20-24, 2017

@EASLnews all this talk about hepatitis elimination makes me optimistic about prospects worldwide & depressed about US landscape #ilc2017

@EASLedu Dr. Reau: 12 wks of #glecaprevir #pibrentasvir cures 99% #HCV G1-5 kidney or liver transplant pts. 1 disc due to AEs #ilc2017

@EASLedu in response to queries, bezafibrate widely approved worldwide since 70s but not US as far as I can see for high lipids. #ilc2017

@EASLedu @PBCers @pbcadvocate Bezafibrate retails for under $70.00/monthin canada, NZ and the U.K. Not FDA approved. #ILC2017

@EASLedu other question is whether there is benefit from starting #UDCA #bezafibrate combo as initial therapy. Studies lacking. #ILC2017

@EASLedu bezafibrate data need to be confirmed but if they are, would represent major advance in #PBC treatment #ilc2017

@EASLedu bezafibrate group: 70% biochemical responders, less itch, most normalized alkphos. Some mild cr but well tolerated #ilc2017

@EASLedu Dr. Coprechot: very impressive data in 2y RCT of bezafibrate vs. placebo among #PBC #UDCA non biochemical reponders #ilc2017

@EASLedu my conclusions: precision medicine in #HCC has not arrived. tumor biopsies should only be done as part of studies #ilc2017

@EASLedu Prof. Galle tackles precision medicine in #HCC? Do we have the knowledge and the tools? #ilc2017

@EASLedu survival differences Asian vs. European largely related to very different treatment cascades not efficacy in my opinion #ilc2017